Skip to main content
. 2023 Sep 22;8(18):e169424. doi: 10.1172/jci.insight.169424

Figure 3. Autologous BM-MSC treatment efficacy in number of relapses and number of immunosuppressive drugs needed to maintain remission.

Figure 3

(A) Single-patient representation of number of relapses in the 12 previous months (full dots, ntot = 16) and in the 12 months after BM-MSC infusions (shaded dots, ntot = 15) shown overall (purple, left panel), in children (blue, central panel), and in adults (red, right panel). Data were compared by Wilcoxon’s test. **P < 0.01. NS, not significant. †One adult patient was lost to follow-up at +8 months, as detailed in Supplemental Table 2. (B) Single-patient representation of number of immunosuppressive drugs at baseline (full dots, ntot = 16) and at +12 months after BM-MSC infusions (shaded dots, ntot = 15) shown overall (purple, left panel), in children (blue, central panel), and in adults (red, right panel). Data were compared by Wilcoxon’s test. *P < 0.05, **P < 0.01. NS, not significant. †One adult patient was lost to follow-up at +8 months, as detailed in Supplemental Table 2.